Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amsterdam Molecular Therapeutics BV

Division of uniQure NV
www.amtbiopharma.com

Latest From Amsterdam Molecular Therapeutics BV

STOCKWATCH: EU conditional approvals – what gives?

The adjectives used to describe PTC Therapeutics' conditional European approval for its drug Translarna (ataluren) for Duchenne muscular dystrophy ranged from 'surprise' to 'historic' and helped to bolster PTC's share price by 30% by the close of the day of the announcement (scripintelligence.com, 23 May 2014). PTC's regulatory success was certainly unexpected as it followed a previous rejection by CHMP which cited limited evidence of Translarna's efficacy (scripintelligence.com, 24 January 2014).

Cancer Orthopedics

Deals Of The Week Looks At Pricing Conundrums

New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.

BioPharmaceutical Medical Device

uniQure Gets Its Groove On: An Interview With CEO Jörn Aldag

UniQure made history in 2012 for winning approval in the EU for the first gene therapy accepted by regulators in a major market. CEO Jörn Aldag shares his views on uniQure's ambitious expansion plans.

BioPharmaceutical Manufacturing

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • uniQure NV
  • Senior Management
  • John Aldag, CEO
    Andre Verwei, CFO
    Janneke de Wal, MD, Dir., Global Mktg. & Sales
    Carlos R Camozzi, MD, PhD, CMO
  • Contact Info
  • Amsterdam Molecular Therapeutics BV
    Phone: (31) 20 566 7394
    P.O. Box 22506 Amsterdam, 1100 DA
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register